2023
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial
Ross J, Perumal R, Wolf A, Zulu M, Guzman K, Seepamore B, Reis K, Nyilana H, Hlathi S, Narasimmulu R, Cheung Y, Amico K, Friedland G, Daftary A, Zelnick J, Naidoo K, O’Donnell M. Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial. Trials 2023, 24: 776. PMID: 38037105, PMCID: PMC10691086, DOI: 10.1186/s13063-023-07520-9.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisAdherence support interventionsAntiretroviral therapyTreatment regimensAdherence supportPrimary outcomeTreatment supportPsychosocial supportMDR-TB treatment regimensUndetectable HIV viral loadSupport interventionsIntegrase strand transfer inhibitorsAdherence support strategiesComposite clinical outcomeMDR-TB regimensNegative TB culturesCombination antiretroviral therapyComposite primary outcomeHIV treatment outcomesHIV viral loadDrug-resistant tuberculosisStandard of careNew treatment regimensDifferentiated service deliveryStrand transfer inhibitors
2018
Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa
Bionghi N, Daftary A, Maharaj B, Msibi Z, Amico K, Friedland G, Orrell C, Padayatchi N, O’Donnell M. Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa. BMC Infectious Diseases 2018, 18: 171. PMID: 29642874, PMCID: PMC5896111, DOI: 10.1186/s12879-018-3080-2.Peer-Reviewed Original ResearchConceptsAnti-retroviral therapySeven-day recallPill countMedication adherenceWisepill deviceTreatment regimensTB/HIV co-infected patientsHIV co-infected adultsHIV co-infected patientsDrug-resistant tuberculosis treatmentCo-infected adultsCo-infected patientsDR-TB treatmentPilot study patientsWeekly pill countsComplex treatment regimensElectronic pill boxesLevel of adherenceTB regimensAdherence supportAntiretroviral therapyHIV patientsStudy patientsMethodsEligible patientsNew antimycobacterial drugs
2009
Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis
Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. The Lancet Infectious Diseases 2009, 9: 153-161. PMID: 19246019, DOI: 10.1016/s1473-3099(09)70041-6.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisTreatment outcomesHIV statusTreatment regimensStrong patient supportProportion of patientsPatient's HIV statusTuberculosis treatment programmesHigher treatment successSuccessful treatment outcomePublic health concernStandardised regimensMDR tuberculosisObserved therapyPatient populationTreatment completionTreatment successInclusion criteriaPatient supportTherapeutic studiesClinical reportsTreatment approachesTreatment durationPatientsSystematic review
2004
Therapeutic Response of HIV-1 Subtype C in African Patients Coinfected with either Mycobacterium tuberculosis or Human Herpesvirus-8
Cassol E, Page T, Mosam A, Friedland G, Jack C, Lalloo U, Kopetka J, Patterson B, Esterhuizen T, Coovadia HM. Therapeutic Response of HIV-1 Subtype C in African Patients Coinfected with either Mycobacterium tuberculosis or Human Herpesvirus-8. The Journal Of Infectious Diseases 2004, 191: 324-332. PMID: 15633090, DOI: 10.1086/427337.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountDrug Therapy, CombinationFemaleHerpesvirus 8, HumanHIV InfectionsHIV-1HumansMaleMiddle AgedMycobacterium tuberculosisReverse Transcriptase InhibitorsRNA, ViralSarcoma, KaposiTreatment OutcomeTuberculosis, PulmonaryViral LoadConceptsKaposi's sarcomaHIV-1Opportunistic infectionsViral loadAfrican patientsUndetectable HIV-1 RNA levelsCell countHIV-1 RNA levelsPlasma HIV-1 levelsHuman immunodeficiency virus (HIV) infectionHIV-1 subtype CKaplan-Meier survival analysisMycobacterium tuberculosisHIV-1 levelsImmunodeficiency virus infectionProportion of patientsTarget cell availabilityHuman herpesvirus 8Immune activationTreatment regimensSubtype CTherapeutic responseTreatment outcomesVirus infectionHerpesvirus 8